枸地氯雷他定联合匹多莫德治疗慢性荨麻疹的临床效果观察及对患者免疫功能影响的研究
|
摘要
目的探讨枸地氯雷他定联合匹多莫德治疗慢性荨麻疹的临床疗效、安全性及对患者免疫功能的影响。方法将入选的120例慢性荨麻疹患者采用随机数字表法分为两组,治疗组(68例)予枸地氯雷他定联合匹多莫德治疗,对照组(52例)仅予枸地氯雷他定治疗。疗程结束后比较两组患者的临床疗效、T淋巴细胞亚群,并观察患者不良反应发生情况。结果治疗4周后,治疗组症状体征得分低于对照组(P<0.05),有效率为95.59%,明显高于对照组75.00%(χ~2=9.10,P<0.05)。治疗组CD_4~+细胞分数、CD_4~+/CD_8~+细胞比值高于对照组,CD_8~+细胞分数低于对照组,差异有统计学意义(P<0.05)。结论采用枸地氯雷他定联合匹多莫德治疗慢性荨麻疹临床疗效显著,可有效改善患者的细胞免疫功能,提高临床治疗效果,且不良反应发生率低。
Objective To investigate the clinical effects, safety and effects on immune functions of desloratadine citrate combined with pidotimod granule in the treatment of chronic urticaria. Methods One hundred and twenty patients with chronic urticaria were divided into two groups by random number table. The treatment group(68 cases) was treated with desloratadine citrate combined with pidotimod, while the control group(52 cases) was treated with desloratadine citrate only. The clinical efficacy and T lymphocyte subsets of the two groups were compared after the course of treatment, and the occurrence of adverse reactions was observed. Results After 4 weeks of treatment, the score of symptoms and signs in the treatment group was lower than that in the control group(P<0.05), the effective rate was 95.59%, which was significantly higher than that in the control group 75.00%(χ~2=9.10, P<0.05). The number of CD_4~+ cells and the ratio of CD_4~+ cells to CD_8~+ cells in the treatment group were higher than those in the control group, and the number of CD_8~+ cells in the treatment group was lower than that in the control group(P<0.05). Conclusion The clinical efficacy of desloratadine citrate combined with pidotimod in the treatment of chronic urticaria is remarkable. It can effectively improve the cellular immune function of patients, improve the clinical efficacy, and the incidence of adverse reactions is low.
Objective To investigate the clinical effects, safety and effects on immune functions of desloratadine citrate combined with pidotimod granule in the treatment of chronic urticaria. Methods One hundred and twenty patients with chronic urticaria were divided into two groups by random number table. The treatment group(68 cases) was treated with desloratadine citrate combined with pidotimod, while the control group(52 cases) was treated with desloratadine citrate only. The clinical efficacy and T lymphocyte subsets of the two groups were compared after the course of treatment, and the occurrence of adverse reactions was observed. Results After 4 weeks of treatment, the score of symptoms and signs in the treatment group was lower than that in the control group(P<0.05), the effective rate was 95.59%, which was significantly higher than that in the control group 75.00%(χ~2=9.10, P<0.05). The number of CD_4~+ cells and the ratio of CD_4~+ cells to CD_8~+ cells in the treatment group were higher than those in the control group, and the number of CD_8~+ cells in the treatment group was lower than that in the control group(P<0.05). Conclusion The clinical efficacy of desloratadine citrate combined with pidotimod in the treatment of chronic urticaria is remarkable. It can effectively improve the cellular immune function of patients, improve the clinical efficacy, and the incidence of adverse reactions is low.
引文
[1]詹淑霞,林一平,肖佐环,等.匹多莫德分散片治疗慢性荨麻疹疗效观察[J].中国麻风皮肤病杂志,2011,27(7):516-517.
[2]种树彬.匹多莫德联合地氯雷他定治疗慢性荨麻疹疗效观察[J].中国实用医药,2015,10(15):43.
[3]张禁,杨颜龙,姜功平,等.地氯雷他定联合复方甘草酸苷治疗慢性荨麻疹66例临床观察[J].中国皮肤性病学杂志,2013,27(7):755-756.
[4]毛越苹,谭国珍,张楚怡,等.枸地氯雷他定片治疗慢性特发性荨麻疹有效性与临床安全性分析[J].中国皮肤性病学杂志,2014,28(9):974-976.
[5]Zuberbier T,Asero R,Bindslevjensen C,et al.EAACI/GA(2)LEN/EDF/WAO guideline:definition,classification and diagnosis of urticaria[J].Allergy,2009,64(10):1417-1426.
[6]吴伊旋,沈惠风.慢性荨麻疹部分发病机制的研究进展[J].临床皮肤科杂志,2008,37(2):136-137.
[7]闫毅,刘瑞珍,徐德钢.枸地氯雷他定与依匹斯汀治疗慢性荨麻疹随机对照研究[J].中华皮肤科杂志,2015,48(1):54-56.
[8]Kaplan AP,Greaves M.Pathogenesis of chronic urticaria[J].Clin Exp Allergy,2009,39(6):777-787.
[9]Benetti GP,Fugazza L,Stramba Badiale M,et al.Ex vivo evaluation of pidotimod activity on cell-mediated immunity[J].Arzneimittel-Forschung,1994,44(12A):1476-1479.
[10]Asman SM,Abdel-Rehin,Dina S,et al.Vitamin D level among Egyptian patients with chronic spontaneous urticaria and its relation to severity of the disease[J].Egypt J Immunol,2014,21(2):85-90.
[11]Savic S,Marsland A,McKay D,et al.Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care[J].Allergy Asthma Clin Immunol,2015,11(1):21.
[12]Sánchez-Borges M,Ansotegui I,Jimenez JM,et al.Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria[J].World Allergy 0rgan J,2014,7(1):33-36.
[13]Song Z,Zhal Z,Zhong H,et a1.Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria[J].PLo S One,2013,8(5):142-143.
[2]种树彬.匹多莫德联合地氯雷他定治疗慢性荨麻疹疗效观察[J].中国实用医药,2015,10(15):43.
[3]张禁,杨颜龙,姜功平,等.地氯雷他定联合复方甘草酸苷治疗慢性荨麻疹66例临床观察[J].中国皮肤性病学杂志,2013,27(7):755-756.
[4]毛越苹,谭国珍,张楚怡,等.枸地氯雷他定片治疗慢性特发性荨麻疹有效性与临床安全性分析[J].中国皮肤性病学杂志,2014,28(9):974-976.
[5]Zuberbier T,Asero R,Bindslevjensen C,et al.EAACI/GA(2)LEN/EDF/WAO guideline:definition,classification and diagnosis of urticaria[J].Allergy,2009,64(10):1417-1426.
[6]吴伊旋,沈惠风.慢性荨麻疹部分发病机制的研究进展[J].临床皮肤科杂志,2008,37(2):136-137.
[7]闫毅,刘瑞珍,徐德钢.枸地氯雷他定与依匹斯汀治疗慢性荨麻疹随机对照研究[J].中华皮肤科杂志,2015,48(1):54-56.
[8]Kaplan AP,Greaves M.Pathogenesis of chronic urticaria[J].Clin Exp Allergy,2009,39(6):777-787.
[9]Benetti GP,Fugazza L,Stramba Badiale M,et al.Ex vivo evaluation of pidotimod activity on cell-mediated immunity[J].Arzneimittel-Forschung,1994,44(12A):1476-1479.
[10]Asman SM,Abdel-Rehin,Dina S,et al.Vitamin D level among Egyptian patients with chronic spontaneous urticaria and its relation to severity of the disease[J].Egypt J Immunol,2014,21(2):85-90.
[11]Savic S,Marsland A,McKay D,et al.Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care[J].Allergy Asthma Clin Immunol,2015,11(1):21.
[12]Sánchez-Borges M,Ansotegui I,Jimenez JM,et al.Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria[J].World Allergy 0rgan J,2014,7(1):33-36.
[13]Song Z,Zhal Z,Zhong H,et a1.Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria[J].PLo S One,2013,8(5):142-143.